Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Capital Employed: 2022-2025

Historic Return on Capital Employed for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to -0.72%.

  • Axsome Therapeutics' Return on Capital Employed rose 13.00% to -0.72% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.72%, marking a year-over-year increase of 13.00%. This contributed to the annual value of -0.81% for FY2024, which is 8.00% down from last year.
  • Per Axsome Therapeutics' latest filing, its Return on Capital Employed stood at -0.72% for Q3 2025, which was up 12.92% from -0.83% recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Return on Capital Employed registered a high of -0.39% during Q3 2023, and its lowest value of -0.85% during Q3 2024.
  • For the 3-year period, Axsome Therapeutics' Return on Capital Employed averaged around -0.68%, with its median value being -0.72% (2025).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first climbed by 24bps in 2023, then slumped by 46bps in 2024.
  • Axsome Therapeutics' Return on Capital Employed (Quarterly) stood at -0.75% in 2022, then increased by 24bps to -0.51% in 2023, then crashed by 33bps to -0.84% in 2024, then increased by 13bps to -0.72% in 2025.
  • Its Return on Capital Employed was -0.72% in Q3 2025, compared to -0.83% in Q2 2025 and -0.80% in Q1 2025.